Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer owns rights to R-ketoprofen in development with Sepracor.

Executive Summary

BAYER OWNS RIGHTS TO R-KETOPROFEN IN DEVELOPMENT WITH SEPRACOR and paid the Boulder-based company $1 mil. in licensing fees in late 1994, according to a secondary stock registration document filed by Sepracor with the Securities & Exchange Commission June 9. Sepracor Chief Financial Officer David Southwell misspoke at a May 11 securities analysts conference sponsored by Dillon, Reed when he said the company was working with SmithKline Beecham on the R-ketoprofen form of the analgesic.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel